Srikripa Devarakonda

Stock Analyst at Truist Securities

(0)
# 3906
Out of 5,298 analysts
64
Total ratings
27.27%
Success rate
-9.08%
Average return
18 Stocks
Name Action Price Target Current % Upside Ratings Updated
INCY Incyte
Maintains: Hold
74 72
60.6 18.81% 9 Mar 18, 2025
PTGX Protagonist Therapeutics
Maintains: Strong Buy
60 76
44.46 70.94% 2 Mar 11, 2025
BIIB Biogen
Maintains: Buy
220 210
122.93 70.83% 3 Feb 13, 2025
LLY Eli Lilly
Maintains: Strong Buy
1029 1038
738.4 40.57% 4 Feb 3, 2025
ABBV AbbVie
Maintains: Strong Buy
211 217
186.88 16.12% 3 Feb 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
1126 1004
572.76 75.29% 5 Jan 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
100 43
10 330% 4 Dec 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 32
22.98 39.25% 1 Dec 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
33 50
11.51 334.4% 6 Nov 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
36 45
26.85 67.6% 4 Nov 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
54 53
22.03 140.58% 3 Nov 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
54 54
2.12 2447.17% 1 Sep 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
18 15
5.17 190.14% 7 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
36
9.67 272.29% 1 Jul 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
86 70
37.42 87.07% 4 May 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
80 60
0.57 10426.32% 2 Aug 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
38
n/a n/a 3 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
50 34
n/a n/a 2 Jun 3, 2021